China’s Policies To Promote Life Science Industry
This article was originally published in PharmAsia News
National Development and Reform Commission officials revealed at a recent China Bioindustry Convention that it and 19 other departments have jointly drafted policies on boosting China bioindustry development. Pending approval from the State Council, the policies revolve around incubating life sciences firms at initial start-up phase and developing those in the expansion stage. The document proposes measures for the industrial structure, investment and fundraising, finance and tax, market environment, talent and biological safety to boost the industry. Meanwhile, the draft also takes into consideration practical application to ensure implementation. (Click here for more - Chinese Language)
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.